Chatziralli Irini, Theodossiadis George, Moschos Marilita M, Mitropoulos Panagiotis, Theodossiadis Panagiotis
2nd Department of Ophthalmology, Attikon Hospital, University of Athens, 28, Papanastasiou street, Agios Dimitrios, 17342, Athens, Greece.
2nd Department of Ophthalmology, Henry Dunant Hospital, Athens, Greece.
Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1093-1100. doi: 10.1007/s00417-017-3613-1. Epub 2017 Feb 18.
The objective of this study was to compare the anatomical and functional outcomes of ranibizumab versus aflibercept for the treatment of macular edema due to central retinal vein occlusion (CRVO) in routine clinical practice.
Participants in this observational study included 62 treatment-naïve patients with CRVO who received intravitreal injections of either ranibizumab or aflibercept. The demographic data, best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT) characteristics were evaluated at baseline and at months 1, 2, 3, 6, 12 and 18 post-treatment.
At month 18, the mean BCVA of ranibizumab-treated eyes increased 7.9 letters, compared to 7.4 letters for eyes receiving aflibercept, with a similar number of injections. There was no statistically significant difference between the two groups in letters or in central subfield thickness at month 18. At the end of the follow-up, 50% of patients in the ranibizumab group and 42.9% in the aflibercept group showed complete resolution of macular edema.
Ranibizumab and aflibercept demonstrated similar anatomical and functional outcomes over 18-month follow-up in patients with macular edema due to CRVO, with a similar number of injections.
本研究的目的是在常规临床实践中比较雷珠单抗与阿柏西普治疗视网膜中央静脉阻塞（CRVO）所致黄斑水肿的解剖学和功能学结果。
本观察性研究的参与者包括62例初治CRVO患者，他们接受了玻璃体内注射雷珠单抗或阿柏西普。在基线以及治疗后1、2、3、6、12和18个月评估人口统计学数据、最佳矫正视力（BCVA）和光谱域光学相干断层扫描（SD-OCT）特征。
在第18个月时，接受雷珠单抗治疗的眼睛的平均BCVA提高了7.9个字母，接受阿柏西普治疗的眼睛提高了7.4个字母，注射次数相似。两组在第18个月时字母数或中央子场厚度方面无统计学显著差异。随访结束时，雷珠单抗组50%的患者和阿柏西普组42.9%的患者黄斑水肿完全消退。
在CRVO所致黄斑水肿患者中，经过18个月的随访，雷珠单抗和阿柏西普显示出相似的解剖学和功能学结果，注射次数相似。
